Feb 14, 2024
China's DRG/DIP Reform: Bridging Medical Service Pricing and Supporting Tech Innovation
The DRG/DIP payment reform has curtailed the rapid expansion of China's public hospitals, shifting focus to quality
Kelly Ke
Jan 17, 2024
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure
Jan 03, 2024
Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation
Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
Dec 20, 2023
China Market Access Pathways for Innovative Medicines Infographic
Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access
Dec 06, 2023
NHSA Proposes Launch Price Framework and Aligns Pricing Policies with Drug Lifecycle
At a recent industry investor conference, Weng Linjia, Deputy Director of the Pharmaceutical Pricing and Tender Procurement Department, National Healthcare
Nov 22, 2023
China's Medical Service Pricing Reform: Current State and Future Development
In our last newsletter, we delved into the three fundamental issues connected with medical service pricing in China:
* Fragmented pricing
Nov 08, 2023
China's Medical Service Pricing Reform: 3 Core Challenges
China's medical service pricing reform is pivotal in reshaping China's healthcare landscape, impacting not only inpatient
Oct 25, 2023
Wonder Sir Founder on the State of Rare Disease Patient Organizations in China
This is the last part of my conversation with Wonder Sir founder Chen Yiwei. You can find our interview'
Oct 11, 2023
NHSA Insurance Funding Expert Zheng Jie: Shifting from Excessive Price Reduction to Value-Based Procurement for China's Drug Pricing Dilemma
At the 5th China Rare Disease Cooperation and Exchange Conference, Zheng Jie, the leader of the Insurance Funding Analysis Expert
Sep 27, 2023
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China
“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as